Cancer drug from Aeterna, Keryx receives fast-track status

12/2/2009 | Reuters

The FDA granted fast-track designation to KRX-0401, an experimental cancer drug from Aeterna Zentaris and Keryx Biopharmaceuticals. Aeterna is testing the product in a Phase II trial to treat multiple tumor types and intends to conduct a late-stage study for multiple myeloma.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Abbott
Santa Ana, CA